HC
PCRX icon

Henshaw Capital’s Pacira BioSciences PCRX Stock Holding History

Henshaw Capital’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,512
Closed -$358K – 314
2024
Q2 		$358K Buy
12,512
+196
+2% +$5.58K 0.02% 219
2024
Q1 		$360K Buy
12,316
+2,522
+26% +$77.5K 0.02% 223
2023
Q4 		$330K Buy
9,794
+1,916
+24% +$56.1K 0.02% 229
2023
Q3 		$242K Buy
+7,878
New +$284K 0.01% 254

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Henshaw Capital's PCRX Position: Q3 2024 in Review

Henshaw Capital sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 12,512 shares — an estimated $358K sold.

Henshaw Capital first reported a position in PCRX in Q3 2023 and held it in 4 quarters. The position peaked at $360K in Q1 2024. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.

  • Henshaw Capital reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
  • Henshaw Capital sold 12,512 Pacira BioSciences shares in Q3 2024, an estimated $358K.
  • Henshaw Capital first reported a position in Pacira BioSciences in Q3 2023 and held it in 4 quarters.
  • Henshaw Capital's Pacira BioSciences position peaked at $360K in Q1 2024.
  • 239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.

Based on Henshaw Capital's 13F filing for Q3 2024, filed 28 May 2026.